Recent results published last March 2018, in the Lancet Oncology magazine showed that Larotrectinib, a new drug has 93% response rate in pediatric patients with TRK fusion–positive solid tumors.
What is Larotrectinib?
Larotrectinib is a new novel target therapy that inhibits tropomyosin kinase receptors (TKN), characterized by being very selective to these receptors. This drug is given orally twice a day, and the most common side effects include elevated liver enzymes and nausea.
What is the relationship between TRK and Cancer?
The TRK gene is often fused (attached) to another gen in some types of cancers, because of this abnormal fusion the TRK gene gets activated promoting uncontrolled tumor growth. These fusions have been found in adults and children with cancer. Some rare pediatric cancers that often have TRK fusions include infantile fibrosarcoma, cellular congenital mesoblastic nephroma, and papillary thyroid cancer.
“Every patient with a TRK fusion-positive solid tumor treated on this study had their tumor shrink,”. said Theodore W. Laetsch, MD from the University of Texas’ Southwestern’s Simmons Cancer Center in Dallas and leading author of the phase I/II clinical trials with Larotrectinib.
Learn more about the results of the clinical trials with Larotectinib:
Why are this results so important for pediatric cancer?
TRK fusions in children with solid tumors are rare, but we are seeing many soft tissue sarcomas harboring NTRK fusions, which we did not know before. Traditionally those children receive chemotherapy to shrink the tumor and then would undergo surgery if they respond to chemotherapy. Chemotherapy is genotoxic and has both short- and long-term side effects. Whereas with Larotrectinib, we can achieve better results—the response rate to chemotherapy is not even close to 93%. Said Ramamoorthy Nagasubramanian, MD, read more here.
Clinical trials are currently recruiting patients, for more information click here.